IRONWOOD PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Payments to Acquire Debt Securities, Available-for-sale of $3.24 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-17.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2021-02-17
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2018-09-30 was $750.00K, a 98.13% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2018-03-31 was $2.49M, a 94.44% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2018 was $3.24M, a 98.31% decline from fiscal 2017.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2017 was $191.35M, a 38.49% decline from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2016 was $311.12M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $750.00K derived: sum of 2 quarters · filed 2021-02-17 | $750.00K derived: sum of 3 quarters · filed 2021-02-17 | $3.24M 10-K · filed 2021-02-17 |
| 2018-09-30 | $750.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $750.00K derived: sum of 2 quarters · filed 2019-10-31 | $3.24M 10-Q · filed 2019-10-31 | $63.87M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | $2.49M 10-Q · filed 2019-07-30 | $63.12M derived: sum of 3 quarters · filed 2020-02-13 | $103.14M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $2.49M 10-Q · filed 2019-05-02 | $63.12M derived: sum of 2 quarters · filed 2020-02-13 | $103.14M derived: sum of 3 quarters · filed 2020-02-13 | $149.07M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $60.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $100.65M derived: sum of 2 quarters · filed 2020-02-13 | $146.58M derived: sum of 3 quarters · filed 2020-02-13 | $191.35M 10-K · filed 2020-02-13 |
| 2017-09-30 | $40.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $85.95M derived: sum of 2 quarters · filed 2018-11-06 | $130.73M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $45.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $90.71M 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $44.78M 10-Q · filed 2018-05-04 | |||
| 2016-12-31 | $311.12M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |